The American Journal of Medicine
Volume 122, Issue 1, Supplement , Pages S38-S50 , January 2009

Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008

  • Sandra J. Lewis, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Sandra J. Lewis, MD, Northwest Cardiovascular Institute, 2222 NW Lovejoy #606, Portland, Oregon 97210

References 

  1. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, TX: American Heart Association; 2005;
  2. Insull W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2008;122(suppl):S3–S14
  3. Berenson GS, Pickoff AS. Preventive cardiology and its potential influence on the early natural history of adult heart disease: the Bogalusa Heart Study and the Heart Smart Program. Am J Med Sci. 1995;310(suppl 1):S133–S138
  4. La Rosa JC, Brown CD. Cardiovascular risk factors in minorities. Am J Med. 2005;118:1314–1322
  5. Bays HE. “Sick fat,” metabolic disease, and atherosclerosis. Am J Med. 2008;122(suppl):S26–S37
  6. National Cholesterol Education Program. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143–3421
  7. O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142–2146
  8. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:525–584
  9. McCrindle BW, Urbina EM, Dennison BA, et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, the American Heart Association Council on Cardiovascular Disease in the Young, and the American Heart Association Council on Cardiovascular Nursing Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council on Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948–1967
  10. Nasir K, Budoff MJ, Wong ND, et al. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007;116:619–626
  11. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  12. Schwandt P. The importance of reaching lipid targets: statins and the prevention of atherosclerosis. Int J Clin Pract. 2003;57:396–404
  13. Jacobson TA, Gutkin SW, Harger CR. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Curr Med Res Opin. 2006;22:1065–1073
  14. Grundy SM, Cleeman JI, Merz CNB, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–2016
  16. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute. NIH Publication No. 04-5230, August 2004. www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdfAccessed April 23, 2007
  17. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  18. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation. 2007;115:855–860
  19. Braun LT. Cardiovascular disease: strategies for risk assessment and modification. J Cardiovasc Nurs. 2006;21(suppl 1):S20–S42
  20. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31(1):S12–S54
  21. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association and National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  22. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928
  23. Ridker PM, Danielson E, Fonseca FAH, et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  24. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global CV risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–619
  25. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004;364:685–696
  26. Lescol [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006;October
  27. Mevacor [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2007;December
  28. Niacor [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc; 2003;June
  29. Pravachol [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2007;March
  30. Crestor [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2007;November
  31. Lipitor [prescribing information]. New York, NY: Parke-Davis; 2007;November
  32. Zocor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2007;November
  33. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152–160
  34. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW. Comparison of the efficacy of rosuvastatin versus atorvastatin, simavastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19:689–698
  35. Gotto AM. Establishing the benefit of statins in low-to-moderate risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Atheroscler Suppl. 2007;8:3–8
  36. Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol. 2005;96:1674–1680
  37. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(suppl):89C–94C
  38. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(suppl 8A):77C–81C
  39. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  40. Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. Br J Clin Pharmacol. 2006;61:494–501
  41. Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother. 2007;5:52–63
  42. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study (A randomized controlled trial). JAMA. 2001;285:1711–1718
  43. Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93:1481–1486
  44. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99:673–680
  45. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443
  46. Covington MB. Omega-3 fatty acids. Am Fam Physician. 2004;70:133–140
  47. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098
  48. Chagan L, Ioselovich A, Asherova L, Cheng JW. Use of alternative pharmacotherapy in management of cardiovascular diseases. Am J Manag Care. 2002;8:270–285
  49. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78:965–978
  50. Lee IM, Cook NR, Baziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized, controlled clinical trial. JAMA. 2005;294:56–65
  51. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842–857
  52. Gardner CD, Lawson LD, Block E, Chatterjee LM, Kiazand A, Balise RR, et al. Effect of raw garlic vs. commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med. 2007;167:346–353
  53. Levy HB, Kohlhaas HK. Consideration for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother. 2006;40:290–294

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 To access a slide kit for this article, please click here.

PII: S0002-9343(08)01020-6

doi: 10.1016/j.amjmed.2008.10.016

The American Journal of Medicine
Volume 122, Issue 1, Supplement , Pages S38-S50 , January 2009

Article Tools

* Image Usage & Resolution